ANVISA Clinical Trial Changes Brazil: What You Need to Know

Key Takeaways

Brazil's clinical trial landscape has undergone significant transformation following the implementation of Law 14.874/2024, which fundamentally restructures how oncology and infectious disease clinical trials are regulated and approved. The National Health Surveillance Agency (Agência Nacional de Vigilância Sanitária, ANVISA) has established a decentralized ethical approval process and fixed review timelines, positioning Brazil as an increasingly attractive destination for international clinical trial sponsors. Why it matters: These regulatory changes directly address barriers that previously slowed trial initiation in Latin America's largest pharmaceutical market, potentially reshaping the region's role in global drug development.

Overview of ANVISA Regulatory Changes Under Law 14.874/2024

Law 14.874/2024 represents a comprehensive modernization of Brazil's clinical trial regulatory framework, designed to enhance the country's attractiveness as a site for international pharmaceutical research. The legislation introduces three core structural reforms: decentralization of ethical approvals from a centralized committee to local institutional ethics committees, establishment of fixed ANVISA review timelines, and clarification of post-trial access policies for investigational drugs.

Brazil's role as a key Latin American market for clinical research has been constrained by bureaucratic inefficiencies and unpredictable approval timelines. The new regulatory architecture directly addresses these barriers by creating a more distributed, predictable approval pathway. These changes are particularly significant for oncology and infectious disease trials, therapeutic areas where time-to-initiation is critical for both patients and sponsors seeking to accelerate drug development cycles.

Decentralization of Ethical Approvals: From Central to Local Ethics Committees

Prior to Law 14.874/2024, ethical review of clinical trials in Brazil operated through a centralized committee structure, creating bottlenecks that delayed trial initiation across all therapeutic areas. The new regulatory model delegates ethical approval authority to local institutional review boards (IRBs), commonly known in Brazil as Comitês de Ética em Pesquisa (CEPs). This decentralization fundamentally accelerates the approval process by reducing geographic and administrative centralization.

The shift from centralized to local ethical review mirrors practices in mature regulatory markets, including the United States and European Union, where institutional ethics committees maintain primary authority over trial protocol review and approval. Local ethics committees in Brazil now possess the autonomy to approve study protocols without requiring additional central-level ethical clearance, streamlining operational workflows and reducing administrative redundancy.

For oncology and infectious disease trial sponsors, this decentralization translates directly into faster trial startup timelines. Compared with the previous centralized review model, local committee approval enables sponsors to initiate patient enrollment more rapidly, particularly important in oncology where disease progression and patient accrual timelines are time-sensitive. Academic medical centers and research institutions across Brazil now function with greater operational independence, reducing the administrative burden historically associated with centralizing ethical oversight.

ANVISA Review Timelines: Predictability and Efficiency Gains

ANVISA has established fixed regulatory review timelines of 90 to 120 business days for clinical trial approvals under the new framework. This standardized timeline creates predictability for sponsors, enabling more accurate project planning and resource allocation compared with previous regulatory processes that operated without explicit timeframes.

The 90–120 business day window—approximately 4.5 to 6 months in calendar time—represents a significant efficiency gain for international sponsors accustomed to variable approval durations. This predictable timeline reduces regulatory uncertainty and facilitates advance planning for trial infrastructure, site selection, and patient recruitment strategies. For oncology trials, where patient populations are often geographically dispersed and enrollment windows are narrow, predictable approval timelines enable sponsors to coordinate multi-site activation and patient screening protocols with greater confidence.

Compared with previous ANVISA approval durations, which lacked explicit timelines and often extended beyond one year, the new framework substantially accelerates regulatory decision-making. This efficiency positions Brazil competitively against other Latin American regulatory bodies and mature markets, enhancing sponsor confidence in Brazil as a viable primary or secondary trial site for global development programs.

The predictability of ANVISA's review process also reduces the financial risk associated with extended regulatory waiting periods. Sponsors can now forecast approval timelines with greater accuracy, improving budget forecasting and enabling more efficient allocation of clinical development resources across multiple trial sites and therapeutic programs.

Post-Trial Access (PTA) Limitations: Balancing Patient Access and Sponsor Interests

Law 14.874/2024 establishes a five-year limitation on post-trial access (PTA) to investigational drugs following market approval. Post-trial access refers to the provision of investigational drugs to trial participants after a study concludes, typically extending until the drug receives regulatory approval or the sponsor discontinues development. ANVISA's five-year limitation creates a defined endpoint for sponsor obligations regarding PTA provision, balancing patient access considerations with sponsor intellectual property and commercial interests.

The five-year PTA window reflects a compromise between competing ethical and commercial priorities. Patient advocacy groups prioritize extended access to investigational drugs, particularly in oncology where trial participants may have limited therapeutic alternatives. Conversely, sponsors require defined endpoints for PTA obligations to manage long-term financial and liability exposure. The five-year post-approval window provides a reasonable timeframe for patients to access approved drugs through commercial channels while establishing a clear sponsor obligation endpoint.

Compared with PTA policies in other major regulatory jurisdictions, Brazil's five-year framework aligns broadly with practices in mature markets, though specific PTA policies vary by country and therapeutic area. The European Medicines Agency (EMA) and FDA do not mandate specific PTA durations at the regulatory level; instead, they encourage sponsors to develop individual PTA protocols aligned with ethical principles and trial-specific circumstances. Brazil's explicit five-year framework provides greater clarity for sponsors and patients compared with regulatory systems lacking defined PTA parameters.

For oncology and infectious disease trials, the five-year PTA window carries significant ethical implications. Oncology patients enrolled in failed trials or trials of drugs that do not receive approval may face discontinuation of access to investigational agents. The five-year post-approval window ensures that patients with approved drugs can access them through commercial channels, though this assumes successful market approval and drug availability. Sponsors must carefully design PTA protocols to address patient populations whose investigational drugs do not achieve regulatory approval, a consideration particularly important in oncology where therapeutic alternatives may be limited.

Market and Clinical Implications: Increased Attractiveness for Oncology and Infectious Disease Trials

ANVISA's regulatory reforms are expected to substantially increase Brazil's attractiveness as a clinical trial destination for oncology and infectious disease research. The combination of decentralized ethical approvals, predictable ANVISA review timelines, and clarified PTA policies reduces bureaucratic delays and regulatory uncertainty, key barriers that historically deterred international sponsors from prioritizing Brazil as a trial site.

Brazil's large patient population, established academic medical infrastructure, and growing clinical research capacity position the country to capture increased trial activity following these regulatory reforms. Oncology trials particularly benefit from Brazil's diverse patient demographics and disease prevalence, enabling sponsors to recruit representative patient populations for global development programs. Infectious disease trials also stand to benefit, as Brazil faces significant disease burdens in areas including tuberculosis, dengue, and HIV, creating patient populations aligned with therapeutic development priorities.

Foreign investment in Brazilian clinical research infrastructure is expected to increase as sponsors redirect trial resources to jurisdictions with more predictable regulatory pathways. This investment benefits local academic medical centers, contract research organizations (CROs), and healthcare institutions through increased trial activity, employment opportunities, and technology transfer. Patient populations gain potential access to innovative oncology and infectious disease therapies through trial participation, accelerating the availability of novel treatments in Brazil relative to markets with slower trial initiation timelines.

Sponsors adapting to the new regulatory environment must develop protocols aligned with local ethics committee expectations and ANVISA submission requirements. The decentralized ethics review model requires sponsors to engage directly with institutional review boards across multiple trial sites, necessitating more granular regulatory and operational planning compared with centralized approval models. However, this distributed approach ultimately accelerates overall trial timelines by eliminating centralized review bottlenecks.

Future Outlook: Sustaining Brazil's Clinical Trial Ecosystem Post-Reform

Law 14.874/2024 establishes the regulatory foundation for Brazil's evolution as a mature clinical trial destination, but sustained competitiveness requires continued investment in research infrastructure and regulatory capacity. Long-term success depends on ANVISA's effective implementation of the new review timelines and ongoing collaboration with local ethics committees to ensure consistent, high-quality ethical review across trial sites.

Further regulatory refinements are anticipated as ANVISA and Brazilian stakeholders gain experience with the new decentralized framework. Potential areas for future optimization include harmonization of local ethics committee standards to ensure consistent protocol review across Brazil, development of expedited review pathways for trials in priority therapeutic areas, and clarification of PTA policies for specific disease contexts.

Capacity building in local ethics committees and academic research centers is critical to sustaining the benefits of regulatory reform. Investment in training, standardization of review processes, and technology infrastructure will enable local committees to maintain high review standards while meeting ANVISA's 90–120 business day approval timelines. Academic medical centers and CROs must expand clinical research infrastructure to accommodate increased trial activity resulting from regulatory reform.

ANVISA's role in monitoring and optimizing implementation of Law 14.874/2024 will be essential to ensuring that regulatory reforms achieve intended outcomes. Ongoing assessment of trial initiation timelines, ethics committee performance, and sponsor satisfaction will enable ANVISA to identify implementation challenges and refine the regulatory framework to maximize Brazil's competitive position as a clinical trial destination.

Frequently Asked Questions

References

1. Brazil's Law 14.874/2024: Regulatory modernization establishing decentralized ethical approvals, ANVISA review timelines of 90–120 business days, and post-trial access limitations for clinical trials in oncology and infectious disease therapeutic areas.